House E&C Committee Questions FDA, CMS About Scope of LDT Regulatory Problem | GenomeWeb

NEW YORK (GenomeWeb) – The US Food and Drug Administration and the Centers for Medicare & Medicaid Services presented a unified front before Congress today, making the case that the FDA needs to play a leading role in evaluating the safety and efficacy of laboratory-developed tests (LDTs) and that CMS doesn't have the expertise or resources to take up the task as some in the lab and pathology community have suggested.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.